WINNERS CIRCLE!

[Depcom]

$FRZT Ready to Move
Freeze Tag Announces Garfield GO Marketing Plans

Source: InvestorsHub NewsWire


New Game Garfield GO To Launch Tomorrow

TUSTIN, CA - June 12, 2017 - InvestorsHub NewsWire - Freeze Tag (OTC: FRZT), a leading creator of mobile social games, today announced marketing plans for its new Garfield GO, a free-to-play, augmented reality treasure hunting game.

Were excited to announce our marketing plans to all of the fans who are anticipating the launch of the first augmented reality Garfield adventure, said Craig Holland, CEO of Freeze Tag. Word-of-mouth promotion will be an important part of the marketing of the game, so we invite Garfield and Freeze Tag fans everywhere to download and share the game with their friends.

Freeze Tag disclosed that the Garfield GO marketing plans include coordinating press releases with Paws Inc. and social media postings with Paws on the Garfield Facebook and Twitter feeds. Freeze Tag will be running Facebook advertising promotions and an email promotional campaign to their database of gamers. In addition, strategic partner Munzee is promoting the Garfield GO game to their active player base across the USA and Canada.

The Garfield GO! mobile game is the first collaboration between Freeze Tag and strategic partner, Munzee the next generation in global scavenger hunt games. To learn more about Munzee, go to www.munzee.com.

To learn more about Garfield GO, please visit the games website at www.garfieldgo.com.

About GARFIELD
GARFIELD was born on the comics pages on June 19, 1978. The creation of cartoonist Jim Davis, GARFIELD is a humorous strip centered on the lives of a quick-witted orange cat who loves lasagna, coffee, and his remote control; Jon Arbuckle, his owner; and Odie, a sweet but dumb dog. GARFIELD was introduced to the world in just 41 newspapers and is now the most widely syndicated comic strip ever, appearing in 2100 newspapers. The strip, distributed by Universal Press, is read by over 220 million people each day and is translated into 42 languages.
Follow Garfield on Facebook (facebook.com/Garfield), Twitter (twitter.com/Garfield), Instagram (instagram.com/garfield_real) and YouTube (youtube.com/garfieldandfriends), and visit garfield.com, and Garfields free educational site, professorgarfield.org.

About MUNZEE Inc.
With almost 6 million locations worldwide and hundreds of thousands of players, Munzee is a social platform that blends gamification, geolocation and marketing elements into an experience that rewards players for going places in the physical world. Utilizing QR code and GPS technology, Munzee is able to validate a persons location and provide them points to level up in the various Munzee mobile applications. The Munzee suite of applications includes Munzee, our flagship product, Eventzee, a photo scavenger hunt useful for corporate training and trade shows, and WallaBee, an addictive collecting game with over 2,000 beautifully drawn digital cards.

About Freeze Tag, Inc.
Freeze Tag, Inc. is a leading creator of mobile social games that are fun and engaging for all ages. Based on a free-to-play business model that has propelled games like Pokemon Go and Candy Crush Saga to worldwide success, we employ state-of-the-art data analytics and proprietary technology to dynamically optimize the gaming experience for revenue generation. Players can download and enjoy our games for free, or they can purchase virtual items and additional features within the game to increase the fun factor. Our games encourage players to compete and engage with their friends on major social networks such as Facebook and Twitter. Founded by gaming industry veterans, Freeze Tag has launched several successful mobile games including the number one hit series Victorian Mysteries and Unsolved Mystery Club, as well as digital entertainment like Etch A Sketch. Freeze Tag games have been downloaded millions of times on the Apple, Amazon and Google app stores.

Contact:
[e-mail]
714-210-3850 x26

[Depcom]

$DCTH at .021

[Depcom]

$CLSN conference call in progress and up 9% so far today.

[Depcom]

$DXTR great opportunity for a double off bottom here of .24

[Depcom]

$CLSN - Celsion Corporation to Hold First Quarter 2017 Financial Results Conference Call on Friday, May 12, 2017

Source: GlobeNewswire Inc.

Celsion Corporation (NASDAQ:CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter ended March 31, 2017 and provide an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin and GEN-1, an IL-12 DNA plasmid vector formulated into a nanoparticle with a non-viral delivery system at 11:00 a.m. EDT on Friday, May 12, 2017. To participate in the call, interested parties may dial 1-888-282-4591 (Toll-Free/North America) or 1-719-457-2605 (International/Toll) and ask for the Celsion Corporation 1st Quarter 2017 Earnings Call (Conference Code: 4060768) to register ten minutes before the call is scheduled to begin. The call will also be broadcast live over the internet at www.celsion.com.
The call will be archived for replay on Friday, May 12, 2017 and will remain available until Friday, May 26, 2017. The replay can be accessed at 1-888-203-1112 (Toll-Free/North America) or 1-719-457-0820 (International/Toll) using Conference Code: 4060768. An audio replay of the call will also be available on the Company’s website, www.celsion.com, for 90 days after 2:00 p.m. EDT on Friday, May 12, 2017.

About Celsion Corporation

Celsion is a fully-integrated oncology company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. The Company's lead program is ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in Phase III development for the treatment of primary liver cancer and in Phase II development for the treatment of recurrent chest wall breast cancer. The pipeline also includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian and brain cancers. Celsion has two platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies. For more information on Celsion, visit our website: http://www.celsion.com. (CLSN-FIN).


Celsion Investor Contact

Jeffrey W. Church
Sr. Vice President and CFO
609-482-2455
[e-mail]

[Depcom]

$CLSN up this am. Conference call due to start soon on financials / quarterly.

[Depcom]

$DXTR - Didn't see the overnight dip coming but gave me an opportunity to load at the ground at .24 but this is really undervalued at .24

[Depcom]

$DXTR starter at .52 - 8 million shares in float and looking for bottom bounce here. target of .90

[Depcom]

$APTO bid support growing. Pre Market was hitting $1.30 but were holding $1.20 with no problem. Makes my target of $1.75 to $2 look attainable. Alerted at .86 as a bottom bounce play on Friday.

[Depcom]

$RJDG volume a bit light so far, in at .02

[Depcom]

$APTO holding $1 bid. First target $1.35 but looking for $1.75-$2

[Depcom]

$APTO holding .96, some resistance at .97. WE know once we break $1 and hold it, the volume should come.

[Depcom]

$APTO moving up steadily, holding bid support. Bottom bounce play entered on Friday at .86. Ask is now .94 with 12.74 shares outstanding as of December 16.

[Depcom]

$APTO
Typo on my last post there are 12.74 million shares outstanding.

[Depcom]

$APTO hits .92 after hours.
Alerted Friday at .86 as a bottom bounce play.
12.47 million shares outstanding.
Recently a $4 pps. First target $1.36.
Expecting this to hit $1.75 to $2 range

[Depcom]

$APTO closed at .90. Looking next for that $1 break and bid support to hold at that level.

[Depcom]

$APTO - 12.74 million shares outstanding
bottom bounce play
just passed 50/200 day moving average
alerted at .86 Friday
First target $1.36 but i would be looking for 1.75 to $1.86
This was $4 fairly recently

[Depcom]

$APTO

Aptose is focused on the development of CG’806, an oral preclinical compound being developed for patients with FLT3-driven acute myeloid leukemia (AML) and certain BTK-driven B-cell malignancies.



About Aptose

Aptose Biosciences is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. Aptose is advancing new therapeutics focused on novel cellular targets on the leading edge of cancer research coupled with companion diagnostics to identify the optimal patient population for our products. The company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. For further information, please visit www.aptose.com.

[Depcom]

$APTO

Aptose Biosciences to Participate at the Bloom Burton & Co. Healthcare Investor Conference 2017

https://finance.yahoo.com/news/aptose-biosciences-participate-bloom-burton-123000637.html

[Depcom]

$APTO - .86 bottom bounce play.

52 week low was .78 with a high of $4.29 there could be a substantial move
Market Cap is 16.52 Million

Recently reported they will announce higher cash flow from 4th quarter 2016 to first quarter 2017. Conference call scheduled for May 11, 2017.

https://finance.yahoo.com/news/aptose-release-first-quarter-ended-123000384.html

[Depcom]

$APTO big buys starting to hit.

[Depcom]

$APTO a nice bottom play at .86

[Depcom]

$APTO starter position at .89 pps

[Depcom]

$PLUG trending upward after hours.

[Depcom]

$PLUG on a slight pullback but only a nudge under 50 day moving average and only a few cents below 200 day moving average. If we can break the 200 day we could see a sustained move from here.

[Depcom]

$ZPAS took a 35-40% profit the other day but still moving up steadily.

[Depcom]

FRZT with a target of .0008 as initial target.

[Depcom]

$PLUG up another .09 cents. No major resistance. I would place my target at $4

[Depcom]

Current starter positions in $GLUU, $ZPAS & $RJDG

[Depcom]

$EAPH going to have upside in the coming month. Expecting more updates this month as per PR.

Easton Pharmaceuticals and BMV Medica Announces First Shipment of “Gynofit” To Multi-National Pharmaceutical Company

Source: InvestorsHub NewsWire


Easton Pharmaceuticals and BMV Medica Announces First Shipment of “Gynofit” To Multi-National Pharmaceutical Company, Gedeon Richter, Towards Its Purchase Order, Has Been Received For February 16th Product Launch in Puerto Vallarta, Mexico

TORONTO, ON -- February 3, 2017 -- InvestorsHub NewsWire -- Easton Pharmaceuticals, Inc. (OTC:EAPH) announces after having received initial payment towards product purchase from pharmaceutical multi-national Gedeon Richter’s Plc subsidiary - Gedeon Richter Mexico S.A.P.I. de C.V., the first shipment of “Gynofit” bacterial vaginosis treatment has been shipped and received in Mexico in preparation of its product launch in Puerto Vallarta, Mexico for February 16th.

Gedeon Richter will be showcasing the products as it launches its marketing and sales program with a steadily increasing marketing budget over the next 3 years. Easton / BMV will provide sales figures and projections sometime in the next quarter.

"Gynofit" is a natural product treatment for women diagnosed with BV (Bacterial Vaginosis), a condition that affects nearly all women at some point in their lives and is one of the most common reasons for gynecological visits by women. In addition, Gynofit will be promoted for help in maintenance of a healthy vaginal flora. As previously announced, the agreement with Gedeon Richter Mexico S.A.P.I de C.V. provides for annual minimums in return for granting exclusivity. Gedeon Richter Plc and Gedeon Richter Mexico S.A.P.I. de C.V. has committed to a strong marketing plan for Gynofit and its success, which Easton / BMV and Gedeon Richter believe will steadily drive sales in Mexico over the next three years and beyond.

Other News

Easton Pharmaceuticals continues to move forward with its due diligence for the acquisition of revenue generating iBliss Inc., as previously announced and expects to have the transaction completed sometime this month once all terms of the agreement have been agreed to and finalized.

Easton is also confirming that it has entered into negotiations towards acquiring a second revenue generating company possessing strong international sales which could coincide with the closing of iBliss and BMV Medica S.A.

Easton is also in late stage negotiations towards 2 (two) agreements with two 2 (two) medical marijuana companies, one in Jamaica and the other in the US, both expecting to potentially add significant and near term sales to Easton. Updates are expected this month or as they materialize.

Easton also confirms that late stage negotiations are continuing towards Eastons / BMV Medica’s other licensed products (VS-Sense, AL-Sense). Detailed updates expected very shortly

For More Detailed Information On iBliss Visit:

https://iblissvapor.com

For More Detailed Information on Gedeon Richter Plc Visit:

http://www.richter.hu/en-US/Pages/default.aspx

About Easton Pharmaceuticals

Easton Pharmaceuticals is a diversified specialty pharmaceutical company involved in various pharmaceutical sectors and other growing industries. The Company previously developed and owned an FDA-approved wound-healing drug and currently owns topically delivered drugs to treat cancer and other therapeutic products to treat various conditions that are all in various stages of development and approval. Easton has partnered with BMV Medica SA de C.V. and together, own the exclusive distribution rights in Mexico and Latin America for patented women's diagnostic and preventative care products from CommonSense of Israel, along with two generic cancer drugs, Paclitaxel and Docetaxel from BioLyse Pharma of St. Catherine's Ontario, Canada.

For More Information Visit:

http://www.eastonpharmaceuticalsinc.com
http://www.bmvmedica.net
http://ecigmarkets.com
http://finance.yahoo.com/q?s=eaph
https://twitter.com/eastonpharma

Safe Harbor

This news release may contain forward-looking statements or expressions within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"). In particular, when certain words or phrases such as "hope", "positive", "anticipate," "pleased," "plan," "confident that," "believe," "expect," "possible" or "intent to" and similar conditional expressions are expressed, they are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company's financial reports and filings.

Contact Information

Evan Karras
CEO
Tel: [phone]
Tel: [phone]
Email: [e-mail]

[Depcom]

$NGD, $PPCH, $EFFI, $SFOR, $PTX

[Depcom]

$SFOR up 44%

[Depcom]

$PPCH IN AT .0159

[Depcom]

PTX should start moving.

[Depcom]

$PTX at .58 took a position here

[Depcom]

$FREEF - volume is still good, trying to break through .02.
.02 break would be a very positive sign.

$EFFI TRYING TO BREAK .0010 wall here as well. This could be a good run if we break the wall. Company updates have been positive.

[Depcom]

$EFFI UP 50% been waiting on this one to bounce back for me.

[Depcom]

$FREEF 944,500 share buy at .0128

[Depcom]

$FREEF Closed up 14% - initial position opened today at .0135 - 36,000 shares. Target .03-.04. Looking forward to Monday ????

[Depcom]

$FREEF UP 10%

[Depcom]

$FREEF support building at .0013/.0014 level

[Depcom]

Added $FREEF at .0135. Volume has been picking up and we could see a spike. My target is .03 - .04

[SwingKing]

Missed you guys, going to be back posting away in a few days. Good Luck to all.

[Depcom]

Added $SDOC at .093

[Depcom]

$BAA News Out ------ News out: Banro Reports Further High Grade Drill Results and New Mineralized Zone at Namoya
- Drilling at Namoya intersects significant mineralization, including 10.00 metres grading 18.48 g/t Au, 29.00 metres grading 3.84 g/t Au, 16.00 metres grading 4.16 g/t Au, 6.00 metres grading 17.65 g/t Au and 42.00 metres grading 2.29 g/t Au.

- New mineralised zone; Namoya Summit Hanging Wall, discovered at Namoya.


http://www.banro.com/assets/docs/RC-intercections-Feb-2016.pdf

[Depcom]

EFFI shares being held tight, no shaking free shares.

[Depcom]

FREE holding .15, slow but increasing.

[Depcom]

EFFI .004 - patience will pay off

[Depcom]

$FREE at .01 definitely worth a flyer here

[Depcom]

$WILN added at $1.13 and up ever since.